Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $13.5 million.

  • Vistagen Therapeutics' Total Current Liabilities rose 4061.95% to $13.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.5 million, marking a year-over-year increase of 4061.95%. This contributed to the annual value of $12.6 million for FY2025, which is 14618.39% up from last year.
  • Per Vistagen Therapeutics' latest filing, its Total Current Liabilities stood at $13.5 million for Q4 2025, which was up 4061.95% from $13.6 million recorded in Q3 2025.
  • Vistagen Therapeutics' 5-year Total Current Liabilities high stood at $13.6 million for Q3 2025, and its period low was $2.9 million during Q3 2023.
  • Over the past 5 years, Vistagen Therapeutics' median Total Current Liabilities value was $6.3 million (recorded in 2021), while the average stood at $7.2 million.
  • Per our database at Business Quant, Vistagen Therapeutics' Total Current Liabilities crashed by 8488.44% in 2021 and then skyrocketed by 15856.68% in 2024.
  • Over the past 5 years, Vistagen Therapeutics' Total Current Liabilities (Quarter) stood at $6.4 million in 2021, then tumbled by 33.23% to $4.3 million in 2022, then decreased by 2.87% to $4.2 million in 2023, then surged by 131.02% to $9.6 million in 2024, then soared by 40.62% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q4 2025, $13.6 million for Q3 2025, and $11.2 million during Q2 2025.